Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Midostaurin Combined With Standard Chemotherapy in Children With Untreated FLT3-mutated AML
NCT03591510Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Mar 2019
- Primary completion
- May 2029
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 2 trial of midostaurin in acute myeloid leukemia (AML), sponsored by Novartis. Started Mar 2019; status: active, not recruiting.
02
Drugs
midostaurin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03591510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03591510.